Amylyx Pharmaceuticals (NASDAQ: AMLX) insider transactions
In the twelve months to 10 November 2026, executives and directors of Amylyx Pharmaceuticals reported 31 open-market sales of 574,195 shares ($10.1m) and 2 open-market purchases of 11,900 shares ($152,183), by 7 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 5 October 2026 | Milne George M JR | Director | Open-market sale, 10b5-1 plan | −30,000 | $27.70 | 782,881 | Form 4 |
| 10 September 2026 | Klee Justin B. | Co-Chief Executive Officer | Open-market sale | −29,025 | $32.13 | 3,614,495 | Form 4 |
| 10 September 2026 | Klee Justin B. | Co-Chief Executive Officer | Open-market sale | −1,439 | $33.16 | 3,613,056 | Form 4 |
| 10 September 2026 | Cohen Joshua B | Co-Chief Executive Officer | Open-market sale | −29,545 | $32.16 | 3,614,042 | Form 4 |
| 10 September 2026 | Cohen Joshua B | Co-Chief Executive Officer | Open-market sale | −919 | $33.15 | 3,613,123 | Form 4 |
| 10 September 2026 | Mazzariello Gina | Chief Legal Officer | Open-market sale | −9,525 | $32.46 | 190,849 | Form 4 |
| 10 September 2026 | Mazzariello Gina | Chief Legal Officer | Open-market sale | −11 | $33.34 | 190,838 | Form 4 |
| 10 September 2026 | Frates James M | Chief Financial Officer | Open-market sale | −9,768 | $32.27 | 234,667 | Form 4 |
| 10 September 2026 | Frates James M | Chief Financial Officer | Open-market sale | −1,042 | $33.23 | 233,625 | Form 4 |
| 10 September 2026 | Bedrosian Camille L | Chief Medical Officer | Open-market sale | −7,947 | $32.21 | 280,145 | Form 4 |
| 10 September 2026 | Bedrosian Camille L | Chief Medical Officer | Open-market sale | −2,081 | $33.09 | 278,064 | Form 4 |
| 31 August 2026 | Firestone Karen | Director | Option exercise | +25,000 | $1.76 | 91,900 | Form 4 |
| 31 August 2026 | Firestone Karen | Director | Option exercise | +25,000 | $5.05 | 116,900 | Form 4 |
| 18 August 2026 | Cohen Joshua B | Co-Chief Executive Officer | Grant or award | +60,039 | — | 3,643,587 | Form 4 |
| 18 August 2026 | Bedrosian Camille L | Chief Medical Officer | Grant or award | +22,807 | — | 288,092 | Form 4 |
| 18 August 2026 | Mazzariello Gina | Chief Legal Officer | Grant or award | +21,284 | — | 200,374 | Form 4 |
| 18 August 2026 | Klee Justin B. | Co-Chief Executive Officer | Grant or award | +60,039 | — | 3,643,520 | Form 4 |
| 18 August 2026 | Frates James M | Chief Financial Officer | Grant or award | +22,807 | — | 244,435 | Form 4 |
| 10 July 2026 | Mazzariello Gina | Chief Legal Officer | Open-market sale | −15,000 | $17.61 | 179,090 | Form 4 |
| 9 July 2026 | Mazzariello Gina | Chief Legal Officer | Open-market sale | −15,000 | $18.32 | 194,090 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Amylyx Pharmaceuticals page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.